Mapping the Safety Profile of BiologicalsA Disproportionality Analysis Using the WHO Adverse Drug Reaction Database, VigiBase

被引：0
|
作者：
Thijs J. Giezen
Aukje K. Mantel-Teeuwisse
Ronald H.B. Meyboom
Sabine M.J.M. Straus
Hubert G.M. Leufkens
Toine C.G. Egberts
机构：
[1] Utrecht University,Utrecht Institute for Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology
[2] Medicines Evaluation Board,WHO Collaborating Centre for International Drug Monitoring
[3] Uppsala Monitoring Centre,Department of Clinical Pharmacy
[4] University Medical Center Utrecht,undefined
来源：
Drug Safety | 2010年 / 33卷
关键词：
Infliximab; Etanercept; Adalimumab; Teriparatide; System Organ Class;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: Biologicals have specific characteristics, as compared with the small molecule drugs, and carry specific risks. Safety problems, for example infliximab and the risk for tuberculosis, have been identified via spontaneous reports of suspected adverse drug reactions (ADRs). However, in general there is limited data on the nature of spontaneously reported suspected ADRs for biologicals.
引用
收藏
页码：865 / 878
页数：13
相关论文
共 50 条
  • [1] Mapping the Safety Profile of Biologicals A Disproportionality Analysis Using the WHO Adverse Drug Reaction Database, VigiBase
    Giezen, Thijs J.
    Mantel-Teeuwisse, Aukje K.
    Meyboom, Ronald H. B.
    Straus, Sabine M. J. M.
    Leufkens, Hubert G. M.
    Egberts, Toine C. G.
    DRUG SAFETY, 2010, 33 (10) : 865 - 878
  • [2] Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase
    Xuefeng Bai
    Xiahong Lin
    Kainan Zheng
    Xiaoyu Chen
    Xiaohong Wu
    Yinqiong Huang
    Yong Zhuang
    Endocrine, 2020, 69 : 670 - 681
  • [3] Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase
    Bai, Xuefeng
    Lin, Xiahong
    Zheng, Kainan
    Chen, Xiaoyu
    Wu, Xiaohong
    Huang, Yinqiong
    Zhuang, Yong
    ENDOCRINE, 2020, 69 (03) : 670 - 681
  • [4] Immune checkpoint inhibitor-associated thyroid dysfunction: a disproportionality analysis using the WHO Adverse Drug Reaction Database, VigiBase
    Bai, Xuefeng
    Chen, Xiaoyu
    Wu, Xiaohong
    Huang, Yinqiong
    Zhuang, Yong
    Lin, Xiahong
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2020, 182 (01) : 1 - 9
  • [5] Gastrointestinal toxicities associated with immune checkpoint inhibitors: a disproportionality analysis leveraging VigiBase, the WHO Adverse Drug Reaction Database
    Huang, Sifu
    Bai, Xuefeng
    Fang, Taiyong
    Guo, Yanta
    Zheng, Kainan
    Lin, Xiahong
    JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B, 2021, 22 (02): : 156 - 164
  • [6] Antidepressants and fetal death: A systematic review and disproportionality analysis in the WHO safety database (VigiBase ® )
    Desaunay, Pierre
    Eslier, Maxime
    Alexandre, Joachim
    Dreyfus, Michel
    Chretien, Basile
    Guenole, Fabian
    PSYCHIATRY RESEARCH, 2024, 339
  • [7] Metoclopramide and neurological adverse drug reactions: a disproportionality analysis of Vigibase
    Olsson, Erika
    Svendsen, Kristian
    Nordeng, Hedvig
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2017, 39 (01) : 237 - 237
  • [8] Neuropsychological adverse drug reactions of Remdesivir: analysis using VigiBase, the WHO global database of individual case safety reports
    Lee, S.
    Yang, J. W.
    Jung, S. Y.
    Kim, M. S.
    Yon, D. K.
    Lee, S. W.
    Kang, H-C
    Dragioti, E.
    Tizaoui, K.
    Jacob, L.
    Koyanagi, A.
    Salem, J-E
    Kostev, K.
    Lascu, A.
    Shin, J., I
    Kim, J. H.
    Smith, L.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (23) : 7390 - 7397
  • [9] Safety profile of the direct oral anticoagulants: an analysis of the WHO database of adverse drug reactions
    Monaco, Luca
    Biagi, Chiara
    Conti, Valentino
    Melis, Mauro
    Donati, Monia
    Venegoni, Mauro
    Vaccheri, Alberto
    Motola, Domenico
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 83 (07) : 1532 - 1543
  • [10] Safety profiles of BRAF-inhibitors and MEK-inhibitors: analysis of the WHO database of adverse drug reactions, VigiBase®
    Rousset, M.
    Gouverneur, A.
    Arnaud, M.
    Fourrier-Reglat, A.
    Pariente, A.
    Miremont-Salame, G.
    Molimard, M.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2018, 32 : 82 - 82
12345